FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents isolated polyspecific antibodies against a unique epitope in chemokine eotaxine 2, whereby antibodies bind to additional CCR3-binding chemokines. Invention also relates to the use of said antibodies for mitigating migration of different cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte-related disorders, or allergic atopic disorders.
EFFECT: invention provides higher clinical effectiveness in the above diseases.
19 cl, 32 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIKINE ANTIBODIES BINDING TO SEVERAL CC-CHEMOKINES | 2010 |
|
RU2574786C2 |
| ANTIBODIES RAISED TO HUMAN MCP-1 | 2001 |
|
RU2314316C2 |
| ANTIBODY AND CHEMOKINE CONSTRUCTS AND USES THEREOF IN IMMUNOLOGICAL DISORDERS | 2001 |
|
RU2252786C2 |
| ANTAGONISTS AND METHOD OF USING SAID ANTAGONISTS | 2005 |
|
RU2401842C2 |
| ANTIBODY AGAINST CCR5 | 2003 |
|
RU2322454C2 |
| ANTIBODIES TO INTERLEUKIN-6 AND USES THEREOF | 2013 |
|
RU2656162C2 |
| NEUTRALIZING MONOCLONAL HUMAN ANTI-INTERLEUKIN-33 ANTIBODIES | 2014 |
|
RU2709722C1 |
| IL-17A LINKING AGENT AND METHODS FOR USE THEREOF | 2014 |
|
RU2682046C1 |
| NEW MODULATORS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2627176C2 |
| ANTI-NOTCH1 ANTIBODIES | 2011 |
|
RU2622083C2 |
